Nexgel, Inc 8-K, filed Jun 3, 2021
Nexgel, Inc. (NXGL)
About this 8-K
Nexgel, Inc filed this 8-K on June 3, 2021, reporting on events of June 1, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2021
| NEXGEL, INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware | 000-56066 | 26-4042544 | ||
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
|
2150 Cabot Boulevard West, Suite B Langhorne, Pennsylvania |
19067 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (215) 702-8550
(Former name or former address, if changed since last report)
Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| — | — | — |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June 1, 2021, NexGel, Inc. (the “Company”) appointed Adam E. Drapczuk III to replace Adam Levy as the Company’s Chief Financial Officer effective immediately. Mr. Levy will continue to serve as the Company’s President and Chief Executive Officer.
Prior to joining the Company, Mr. Drapczuk, 45, served as Financial Controller for R-Pharm US, a private fully integrated specialty pharmaceutical company focused on commercial opportunities to treat cancer and chronic immune diseases from September 2016 to April 2020 and has remained in a consulting role with the company since then. He also served as Vice President of Finance, CFO, for Inpellis, Inc.; Controller and Director of Finance for Tris Pharma; and Director of Finance for West-Ward Pharmaceuticals Corp. Mr. Drapczuk began his career in accounting and finance at KPMG LLP, servicing the firm’s assurance clients. He received his B.S. in accounting at Susquehanna University in Selinsgrove, PA.
In connection with his appointment, Mr. Drapczuk is expected to receive an initial monthly cash payment of approximately $5,000, though this amount may increase on a month-by-month basis. Other than the foregoing, there are no arrangements or understandings between Mr. Drapczuk and any other persons pursuant to which he was selected to serve as the Company’s Chief Financial Officer. In addition, other than the foregoing, there are no transactions between the Company and Mr. Drapczuk or his immediate family members requiring disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended.
| Item 8.01 | Other Events. |
On June 1, 2021, the Company issued a press release regarding the appointment of Mr. Drapczuk as the Company’s Chief Financial Officer. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference in its entirety.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit | ||
| No. | Description | |
| 99.1 | Press release of NexGel, Inc. issued on June 2, 2021. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | June 3, 2021 | ||
| NEXGEL, INC. | |||
| By: | /s/ Adam Levy | ||
| Adam Levy | |||
| President and Chief Executive Officer | |||
Exhibit 99.1
NEXGEL Appoints Adam Drapczuk as Chief Financial Officer
Mr. Drapczuk Brings Nearly Two Decades of Healthcare Experience to NEXGEL, Successfully Leading Companies Through the IPO Process to Full-Scale Commercialization
LANGHORNE, Pa. – June 1, 2021 – NEXGEL, Inc. (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that it has appointed Adam Drapczuk as Chief Financial Officer, effective immediately. Mr. Drapczuk is a seasoned healthcare executive who has led successful strategic financial initiatives for both privately held and public companies.
“Adam’s proven track record in leading companies through the IPO process to full-scale commercial operations will play a pivotal role in structuring NEXGEL’s business for long-term success,” said Adam Levy, NEXGEL CEO. “As we move through the regulatory process for upcoming products, Adam’s deep industry network, along with his extensive experience with commercializing assets, will ensure that each NEXGEL product is well-positioned to enter the market and achieve success.”
Prior to joining NEXGEL, Mr. Drapczuk served as Financial Controller for R-Pharm US, a fully integrated specialty pharmaceutical company focused on commercial opportunities to treat cancer and chronic immune diseases. He also served as Vice President of Finance, CFO, for Inpellis, Inc.; Controller and Director of Finance for Tris Pharma; and Director of Finance for West-Ward Pharmaceuticals Corp. Mr. Drapczuk began his career in accounting and finance at KPMG LLP, servicing the firm’s assurance clients.
“With several upcoming new products developed specifically for the medical community, as well as various cosmetic products geared toward the consumer market, NEXGEL is at a pivotal moment in the Company’s history as it approaches a number of important near-term milestones,” added Mr. Drapczuk. “I look forward to working closely with Adam and the rest of the NEXGEL management team to take the Company to the next level and further position NEXGEL as the leader in advanced hydrogel solutions across the board.”
Mr. Drapczuk received his B.S. in accounting at Susquehanna University in Selinsgrove, Pa.
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne,
Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more
than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little
to no irritation.
Investor Contacts:
Valter Pinto / Nick Staab
KCSA Strategic Communications
212.896.1254 / 212.896.1254
valter@kcsa.com / nstaab@kcsa.com
Media Contacts:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
ckasunich@kcsa.com / rcona@kcsa.com